Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer

Novel therapies in multiple myeloma

OncoAlert and ecancer - ESMO 2021 Day 4

Disparities in myeloma: Closing the gap

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer

OncoAlert and ecancer - ESMO 2021 Day 3

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis